News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Pharmaceutical Research and Manufacturers of America (PhRMA) Speaks Out Against FDA Biosimilar Flexibility
May 2, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PhRMA has spoken out against FDA plans to allow biosimilar manufacturers flexibility in delivery device and formulation choice.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
·
1 min read
·
Jef Akst
Regulatory
FDA opens Operation TrialBlazer for applications, hoping to reshore early trials
September 15, 2026
·
1 min read
·
Heather McKenzie
Regulatory
Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meeting
September 15, 2026
·
6 min read
·
Heather McKenzie
Psychedelics
Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
September 15, 2026
·
5 min read
·
Michael Gibney
